Intent to Sole Source - Biolegend Oliogos NOI-CC-OLAO-26-004813
Summary
AI-generated · Apr 30, 2026Custom oligos are required by the PACT team at the Clinical Center to enable single-cell copy-number analysis with the Tapestri instrument for CAR-T cell products, to support clinical QC assays. The NIH intends to negotiate a sole-source contract with Biolegend, based on the assertion that only one source can satisfy the requirement (41 U.S.C. 253(c)(1); FAR 6.302-1).
This is not a request for proposals. Other capable vendors may submit a capability statement by email for consideration.
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Biolegend. Acquisition Description: Custom Oligios needed by PACT team at CCE to do single cell copy number analysis with Tapestri instrument for CAR-T cell products to support clinical QC assay. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-004813) by 12:00 PM eastern standard time on 05/08/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
From Special Notice posted on Apr 29, 2026Notice history
1Details
Award Information
Not yet awarded
Agency
Place of Performance
USA